Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #51 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
The company expects double-digit volume growth for the domestic branded formulation (Akumentis) business in the coming quarters and years, driven by new product launches and expansion into adjacent geographies with increased field force. CDMO segment expects continued high teens volume growth; Q2 looks strong with steady API prices trending upwards.
From Akums Drugs & Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- The company expects double-digit volume growth for the domestic branded formulation (Akumentis) business in the coming quarters and years, driven by new product launches and expansion into adjacent geographies with increased field force.
- CDMO segment showed healthy volume growth of over 18% year-on-year; Q2 volume growth also looks strong at high teens, with positive momentum expected to continue.
- Overall volume growth in the industry is expected to sustain, with the company positioned to outperform market growth.
- New manufacturing capacities (e.g., in oral tablets and a new facility in Baddi) coming online by year-end are expected to support volume growth.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Akums is in the process of setting up one more oral manufacturing facility in Baddi, expected to go live by the end of FY27, which will significantly boost oral manufacturing capabilities.
- The capex for this new facility is still under discussion and will be updated once finalized.
- The company has INR1,600 crores of cash on the balance sheet, mostly parked in fixed deposits with nationalized banks, with no debt.
- Akums is open to acquisitions that are value-accretive and strategically rational to the group, indicating potential future inorganic investments.
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Akums Drugs & Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.3K Cr, net profit ₹115 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Akums Drugs & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Akums Drugs & Pharmaceuticals Ltd Q1 FY27 results?
The company expects double-digit volume growth for the domestic branded formulation (Akumentis) business in the coming quarters and years, driven by new product launches and expansion into adjacent geographies with increased field force. CDMO segment expects continued high teens volume growth; Q2 looks strong with steady API prices trending upwards.
What is Akums Drugs & Pharmaceuticals Ltd share price analysis?
Akums Drugs & Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 37.7 with a market cap of ₹11,512 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?
Akums is in the process of setting up one more oral manufacturing facility in Baddi, expected to go live by the end of FY27, which will significantly boost oral manufacturing capabilities.
Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.